November 5, 2020
11:00 a.m. - Noon CT
Free for all participants.
Every clinical and anatomic pathology laboratory in America is affected by new Medicare and Medicaid coding and billing changes that take effect every year on January 1. The year 2021 is no exception, with new codes, revised codes, and deleted codes. Tune in and hear from one of our industry experts and prepare for the 2021 changes today.
Upon completion of this activity, participants should be able to:
- Identify CPT coding changes that will take effect in 2021.
- Describe coverage and payment changes associated with Medicare and various commercial payers.
- Provide an update for molecular coding, billing, and reimbursement.
- Identify and discuss recent billing "snafus" that are seemingly payer-dependent.
Diana Voorhees, M.A., CLS, MT, SH, CLCP, CPCO
DV & Associates
Salt Lake City, UT
The outreach forums are applicable to community hospital laboratory administrators, managers, directors, pathologists, outreach coordinators, marketing representatives, and sales managers.
Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.
State of California
Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for Clinical Laboratory Sciences for the State of California. This program has been approved for 1.0 contact hour.
State of Florida
Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for Supervision/Administration, Quality Control/Quality Assurance, and Safety credit. This program has been approved for 1.0 contact hour.
To obtain credit:
- Register for and participate in the program.
- Complete the evaluation that will be sent to you after the program.
- Generate and print your certificate(s).
Level of instruction for this program is intermediate.
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.
Contact us: firstname.lastname@example.org